Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 212

1.

Bortezomib administered prior to temozolomide depletes MGMT, chemosensitizes glioblastoma with unmethylated MGMT promoter and prolongs animal survival.

Rahman MA, Gras Navarro A, Brekke J, Engelsen A, Bindesbøll C, Sarowar S, Bahador M, Bifulco E, Goplen D, Waha A, Lie SA, Gjertsen BT, Selheim F, Enger PØ, Simonsen A, Chekenya M.

Br J Cancer. 2019 Aug 15. doi: 10.1038/s41416-019-0551-1. [Epub ahead of print]

PMID:
31413318
2.

Pretreatment of Glioblastoma with Bortezomib Potentiates Natural Killer Cell Cytotoxicity through TRAIL/DR5 Mediated Apoptosis and Prolongs Animal Survival.

Gras Navarro A, Espedal H, Joseph JV, Trachsel-Moncho L, Bahador M, Gjertsen BT, Kristoffersen EK, Simonsen A, Miletic H, Enger PØ, Rahman MA, Chekenya M.

Cancers (Basel). 2019 Jul 17;11(7). pii: E996. doi: 10.3390/cancers11070996.

3.

Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia.

Kuusanmäki H, Leppä AM, Pölönen P, Kontro M, Dufva O, Deb D, Yadav B, Brück O, Kumar A, Everaus H, Gjertsen BT, Heinäniemi M, Porkka K, Mustjoki S, Heckman CA.

Haematologica. 2019 Jul 11. pii: haematol.2018.214882. doi: 10.3324/haematol.2018.214882. [Epub ahead of print]

4.

Intracellular Signaling in Key Pathways Is Induced by Treatment with Ultrasound and Microbubbles in a Leukemia Cell Line, but Not in Healthy Peripheral Blood Mononuclear Cells.

Haugse R, Langer A, Gullaksen SE, Sundøy SM, Gjertsen BT, Kotopoulis S, McCormack E.

Pharmaceutics. 2019 Jul 6;11(7). pii: E319. doi: 10.3390/pharmaceutics11070319.

5.

Enhanced T-lymphocyte infiltration in a desmoid tumor of the thoracic wall in a young woman treated with intratumoral injections of the oncolytic peptide LTX-315: a case report.

Jebsen NL, Apelseth TO, Haugland HK, Rekdal Ø, Patel H, Gjertsen BT, Jøssang DE.

J Med Case Rep. 2019 Jun 10;13(1):177. doi: 10.1186/s13256-019-2088-6.

6.

Modulation of phospho-proteins by interferon-alpha and valproic acid in acute myeloid leukemia.

Forthun RB, Hellesøy M, Sulen A, Kopperud RK, Sjøholt G, Bruserud Ø, McCormack E, Gjertsen BT.

J Cancer Res Clin Oncol. 2019 Jul;145(7):1729-1749. doi: 10.1007/s00432-019-02931-1. Epub 2019 May 20.

7.

GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells.

Zhang B, Ayuda-Durán P, Piechaczyk L, Fløisand Y, Safont MM, Karlsen IT, Fandalyuk Z, Tadele D, van Mierlo P, Rowe AD, Robertson JM, Gjertsen BT, McCormack E, Enserink JM.

Haematologica. 2019 May;104(5):e229. doi: 10.3324/haematol.2019.220533. No abstract available.

8.

Titrating Complex Mass Cytometry Panels.

Gullaksen SE, Bader L, Hellesøy M, Sulen A, Fagerholt OHE, Engen CB, Skavland J, Gjertsen BT, Gavasso S.

Cytometry A. 2019 Jul;95(7):792-796. doi: 10.1002/cyto.a.23751. Epub 2019 Apr 9.

PMID:
30964237
9.

Influence of p53 Isoform Expression on Survival in High-Grade Serous Ovarian Cancers.

Bischof K, Knappskog S, Hjelle SM, Stefansson I, Woie K, Salvesen HB, Gjertsen BT, Bjorge L.

Sci Rep. 2019 Mar 27;9(1):5244. doi: 10.1038/s41598-019-41706-z.

10.

Clinical Trials of Repurposing Medicines in Acute Myeloid Leukemia: Limitations and Possibilities in the Age of Precision Therapy.

Andresen V, Gjertsen BT.

Cancer J. 2019 Mar/Apr;25(2):153-163. doi: 10.1097/PPO.0000000000000363. No abstract available.

PMID:
30896540
11.

Philadelphia chromosome positive AML arising from JAK2-positive myelofibrosis.

Brattås MK, Lilleeng K, Hovland R, Lægreid IJ, Vorland M, Leh F, Bruserud Ø, Gjertsen BT, Reikvam H.

Biomark Res. 2018 Nov 21;6:33. doi: 10.1186/s40364-018-0147-6. eCollection 2018.

12.

Global Gene Expression Response in Peripheral Blood Cells of Petroleum Workers Exposed to Sub-Ppm Benzene Levels.

Jørgensen KM, Færgestad Mosleth E, Hovde Liland K, Hopf NB, Holdhus R, Stavrum AK, Gjertsen BT, Kirkeleit J.

Int J Environ Res Public Health. 2018 Oct 27;15(11). pii: E2385. doi: 10.3390/ijerph15112385.

13.

Chronic Myeloid Leukemia Relapsing 25 Years after Allogenic Stem Cell Transplantation.

Reikvam H, Skavland J, Gullaksen SE, Hovland R, Gedde-Dahl T, Bruserud Ø, Gjertsen BT.

Case Rep Hematol. 2018 Sep 23;2018:2045985. doi: 10.1155/2018/2045985. eCollection 2018.

14.

Maternal exposure to gasoline and exhaust increases the risk of childhood leukaemia in offspring - a prospective study in the Norwegian Mother and Child Cohort Study.

Kirkeleit J, Riise T, Bjørge T, Christiani DC, Bråtveit M, Baccarelli A, Mattioli S, Hollund BE, Gjertsen BT.

Br J Cancer. 2018 Oct;119(8):1028-1035. doi: 10.1038/s41416-018-0295-3. Epub 2018 Oct 15.

PMID:
30318517
15.

Cell therapy induced regeneration of severely atrophied mandibular bone in a clinical trial.

Gjerde C, Mustafa K, Hellem S, Rojewski M, Gjengedal H, Yassin MA, Feng X, Skaale S, Berge T, Rosen A, Shi XQ, Ahmed AB, Gjertsen BT, Schrezenmeier H, Layrolle P.

Stem Cell Res Ther. 2018 Aug 9;9(1):213. doi: 10.1186/s13287-018-0951-9.

16.

Inhibition of Tunneling Nanotube (TNT) Formation and Human T-cell Leukemia Virus Type 1 (HTLV-1) Transmission by Cytarabine.

Omsland M, Pise-Masison C, Fujikawa D, Galli V, Fenizia C, Parks RW, Gjertsen BT, Franchini G, Andresen V.

Sci Rep. 2018 Jul 24;8(1):11118. doi: 10.1038/s41598-018-29391-w.

17.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F.

Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.

18.

High expression of the p53 isoform γ is associated with reduced progression-free survival in uterine serous carcinoma.

Bischof K, Knappskog S, Stefansson I, McCormack EM, Trovik J, Werner HMJ, Woie K, Gjertsen BT, Bjorge L.

BMC Cancer. 2018 Jun 25;18(1):684. doi: 10.1186/s12885-018-4591-3.

19.

Two acute myeloid leukemia patient subsets are identified based on the constitutive PI3K-Akt-mTOR signaling of their leukemic cells; a functional, proteomic, and transcriptomic comparison.

Nepstad I, Hatfield KJ, Aasebø E, Hernandez-Valladares M, Brenner AK, Bartaula-Brevik S, Berven F, Selheim F, Skavland J, Gjertsen BT, Reikvam H, Bruserud Ø.

Expert Opin Ther Targets. 2018 Jul;22(7):639-653. doi: 10.1080/14728222.2018.1487401. Epub 2018 Jun 22.

PMID:
29889583
20.

GRP94 rewires and buffers the FLT3-ITD signaling network and promotes survival of acute myeloid leukemic stem cells.

Zhang B, Durán PA, Piechaczyk L, Fløisand Y, Safont MMS, Karlsen IT, Fandalyuk Z, Tadele D, Mierlo PV, Rowe AD, Robertson JM, Gjertsen BT, McCormack E, Enserink JM; Bjørn Tore Gjertsen Group; Emmet McCormack Group.

Haematologica. 2018 May 10. pii: haematol.2018.189399. doi: 10.3324/haematol.2018.189399. [Epub ahead of print]

21.

Drug Repurposing for the Treatment of Acute Myeloid Leukemia.

Andresen V, Gjertsen BT.

Front Med (Lausanne). 2017 Nov 29;4:211. doi: 10.3389/fmed.2017.00211. eCollection 2017. Review.

22.

Phosphoprotein DIGE profiles reflect blast differentiation, cytogenetic risk stratification, FLT3/NPM1 mutations and therapy response in acute myeloid leukaemia.

Forthun RB, Aasebø E, Rasinger JD, Bedringaas SL, Berven F, Selheim F, Bruserud Ø, Gjertsen BT.

J Proteomics. 2018 Feb 20;173:32-41. doi: 10.1016/j.jprot.2017.11.014. Epub 2017 Nov 21.

PMID:
29175091
23.

Disease-stabilizing treatment based on all-trans retinoic acid and valproic acid in acute myeloid leukemia - identification of responders by gene expression profiling of pretreatment leukemic cells.

Reikvam H, Hovland R, Forthun RB, Erdal S, Gjertsen BT, Fredly H, Bruserud Ø.

BMC Cancer. 2017 Sep 6;17(1):630. doi: 10.1186/s12885-017-3620-y.

24.

NK cell dynamics and association with molecular response in early chronic phase chronic myelogenous leukemia (CML-CP) patients treated with nilotinib.

Sopper S, Mustjoki S, Gjertsen BT, Giles F, Hochhaus A, Janssen JJWM, Porkka K, Wolf D.

Leukemia. 2017 Oct;31(10):2264-2267. doi: 10.1038/leu.2017.235. Epub 2017 Jul 10. No abstract available.

PMID:
28744011
25.

JAK1/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML.

Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, Yadav B, Tamborero D, Tang J, Bychkov D, Kontro M, Parsons A, Suvela M, Mayoral Safont M, Porkka K, Aittokallio T, Kallioniemi O, McCormack E, Gjertsen BT, Wennerberg K, Knowles J, Heckman CA.

Blood. 2017 Aug 10;130(6):789-802. doi: 10.1182/blood-2016-02-699363. Epub 2017 Jun 15.

26.

Single cell immune profiling by mass cytometry of newly diagnosed chronic phase chronic myeloid leukemia treated with nilotinib.

Gullaksen SE, Skavland J, Gavasso S, Tosevski V, Warzocha K, Dumrese C, Ferrant A, Gedde-Dahl T, Hellmann A, Janssen J, Labar B, Lang A, Majeed W, Mihaylov G, Stentoft J, Stenke L, Thaler J, Thielen N, Verhoef G, Voglova J, Ossenkoppele G, Hochhaus A, Hjorth-Hansen H, Mustjoki S, Sopper S, Giles F, Porkka K, Wolf D, Gjertsen BT.

Haematologica. 2017 Aug;102(8):1361-1367. doi: 10.3324/haematol.2017.167080. Epub 2017 May 18.

27.

Tyrosine kinase inhibitor therapy-induced changes in humoral immunity in patients with chronic myeloid leukemia.

Rajala HLM, Missiry ME, Ruusila A, Koskenvesa P, Brümmendorf TH, Gjertsen BT, Janssen J, Lotfi K, Markevärn B, Olsson-Strömberg U, Stenke L, Stentoft J, Richter J, Hjorth-Hansen H, Kreutzman A, Mustjoki S.

J Cancer Res Clin Oncol. 2017 Aug;143(8):1543-1554. doi: 10.1007/s00432-017-2378-6. Epub 2017 Mar 23.

PMID:
28337541
28.

Reduced CD62L Expression on T Cells and Increased Soluble CD62L Levels Predict Molecular Response to Tyrosine Kinase Inhibitor Therapy in Early Chronic-Phase Chronic Myelogenous Leukemia.

Sopper S, Mustjoki S, White D, Hughes T, Valent P, Burchert A, Gjertsen BT, Gastl G, Baldauf M, Trajanoski Z, Giles F, Hochhaus A, Ernst T, Schenk T, Janssen JJ, Ossenkoppele GJ, Porkka K, Wolf D.

J Clin Oncol. 2017 Jan 10;35(2):175-184. Epub 2016 Nov 7.

PMID:
28056193
29.

Therapeutic value of clofarabine in younger and middle-aged (18-65 years) adults with newly diagnosed AML.

Löwenberg B, Pabst T, Maertens J, van Norden Y, Biemond BJ, Schouten HC, Spertini O, Vellenga E, Graux C, Havelange V, de Greef GE, de Weerdt O, Legdeur MJ, Kuball J, Kooy MV, Gjertsen BT, Jongen-Lavrencic M, van de Loosdrecht AA, van Lammeren-Venema D, Hodossy B, Breems DA, Chalandon Y, Passweg J, Valk PJ, Manz MG, Ossenkoppele GJ; Dutch-Belgian Hemato-Oncology Cooperative Group (HOVON) and Swiss Group for Clinical Cancer Research (SAKK).

Blood. 2017 Mar 23;129(12):1636-1645. doi: 10.1182/blood-2016-10-740613. Epub 2017 Jan 3.

30.

Tunneling nanotube (TNT) formation is downregulated by cytarabine and NF-κB inhibition in acute myeloid leukemia (AML).

Omsland M, Bruserud Ø, Gjertsen BT, Andresen V.

Oncotarget. 2017 Jan 31;8(5):7946-7963. doi: 10.18632/oncotarget.13853.

31.

Anti-proliferative activity of the NPM1 interacting natural product avrainvillamide in acute myeloid leukemia.

Andresen V, Erikstein BS, Mukherjee H, Sulen A, Popa M, Sørnes S, Reikvam H, Chan KP, Hovland R, McCormack E, Bruserud Ø, Myers AG, Gjertsen BT.

Cell Death Dis. 2016 Dec 1;7(12):e2497. doi: 10.1038/cddis.2016.392.

32.

Sonoporation with Acoustic Cluster Therapy (ACT®) induces transient tumour volume reduction in a subcutaneous xenograft model of pancreatic ductal adenocarcinoma.

Kotopoulis S, Stigen E, Popa M, Safont MM, Healey A, Kvåle S, Sontum P, Gjertsen BT, Gilja OH, McCormack E.

J Control Release. 2017 Jan 10;245:70-80. doi: 10.1016/j.jconrel.2016.11.019. Epub 2016 Nov 18.

PMID:
27871988
33.

A human clinical trial using ultrasound and microbubbles to enhance gemcitabine treatment of inoperable pancreatic cancer.

Dimcevski G, Kotopoulis S, Bjånes T, Hoem D, Schjøtt J, Gjertsen BT, Biermann M, Molven A, Sorbye H, McCormack E, Postema M, Gilja OH.

J Control Release. 2016 Dec 10;243:172-181. doi: 10.1016/j.jconrel.2016.10.007. Epub 2016 Oct 12.

34.

Signaling effects of sodium hydrosulfide in healthy donor peripheral blood mononuclear cells.

Sulen A, Gullaksen SE, Bader L, McClymont DW, Skavland J, Gavasso S, Gjertsen BT.

Pharmacol Res. 2016 Nov;113(Pt A):216-227. doi: 10.1016/j.phrs.2016.08.018. Epub 2016 Aug 16.

35.

HOX gene expression predicts response to BCL-2 inhibition in acute myeloid leukemia.

Kontro M, Kumar A, Majumder MM, Eldfors S, Parsons A, Pemovska T, Saarela J, Yadav B, Malani D, Fløisand Y, Höglund M, Remes K, Gjertsen BT, Kallioniemi O, Wennerberg K, Heckman CA, Porkka K.

Leukemia. 2017 Feb;31(2):301-309. doi: 10.1038/leu.2016.222. Epub 2016 Aug 8.

PMID:
27499136
36.

Elevated monocyte phosphorylated p38 in nearby employees after a chemical explosion.

Sulen A, Lygre SH, Hjelle SM, Hollund BE, Gjertsen BT.

Sci Rep. 2016 Jul 6;6:29060. doi: 10.1038/srep29060.

37.

The HDACi Panobinostat Shows Growth Inhibition Both In Vitro and in a Bioluminescent Orthotopic Surgical Xenograft Model of Ovarian Cancer.

Helland Ø, Popa M, Bischof K, Gjertsen BT, McCormack E, Bjørge L.

PLoS One. 2016 Jun 28;11(6):e0158208. doi: 10.1371/journal.pone.0158208. eCollection 2016.

38.

Safety and efficacy of the combination of pegylated interferon-α2b and dasatinib in newly diagnosed chronic-phase chronic myeloid leukemia patients.

Hjorth-Hansen H, Stentoft J, Richter J, Koskenvesa P, Höglund M, Dreimane A, Porkka K, Gedde-Dahl T, Gjertsen BT, Gruber FX, Stenke L, Eriksson KM, Markevärn B, Lübking A, Vestergaard H, Udby L, Bjerrum OW, Persson I, Mustjoki S, Olsson-Strömberg U.

Leukemia. 2016 Sep;30(9):1853-60. doi: 10.1038/leu.2016.121. Epub 2016 May 2.

PMID:
27133821
39.

Leukemic Stem Cell Quantification in Newly Diagnosed Patients With Chronic Myeloid Leukemia Predicts Response to Nilotinib Therapy.

Thielen N, Richter J, Baldauf M, Barbany G, Fioretos T, Giles F, Gjertsen BT, Hochhaus A, Schuurhuis GJ, Sopper S, Stenke L, Thunberg S, Wolf D, Ossenkoppele G, Porkka K, Janssen J, Mustjoki S.

Clin Cancer Res. 2016 Aug 15;22(16):4030-8. doi: 10.1158/1078-0432.CCR-15-2791. Epub 2016 Mar 22.

40.

Single-cell proteomics: potential implications for cancer diagnostics.

Gavasso S, Gullaksen SE, Skavland J, Gjertsen BT.

Expert Rev Mol Diagn. 2016;16(5):579-89. doi: 10.1586/14737159.2016.1156531. Epub 2016 Mar 21. Review.

PMID:
26895397
41.

Hydroxyurea synergizes with valproic acid in wild-type p53 acute myeloid leukaemia.

Leitch C, Osdal T, Andresen V, Molland M, Kristiansen S, Nguyen XN, Bruserud Ø, Gjertsen BT, McCormack E.

Oncotarget. 2016 Feb 16;7(7):8105-18. doi: 10.18632/oncotarget.6991.

42.

Post-remission treatment with allogeneic stem cell transplantation in patients aged 60 years and older with acute myeloid leukaemia: a time-dependent analysis.

Versluis J, Hazenberg CL, Passweg JR, van Putten WL, Maertens J, Biemond BJ, Theobald M, Graux C, Kuball J, Schouten HC, Pabst T, Löwenberg B, Ossenkoppele G, Vellenga E, Cornelissen JJ; HOVON and SAKK Leukemia Groups.

Lancet Haematol. 2015 Oct;2(10):e427-36. doi: 10.1016/S2352-3026(15)00148-9. Epub 2015 Sep 18.

PMID:
26686044
43.

Development of Personalized Molecular Therapy for Acute Myeloid Leukemia.

Engen CB, Hajjar E, Gjertsen BT.

Curr Pharm Biotechnol. 2016;17(1):20-9. Review.

PMID:
26420051
44.

4-Alkylated Silver-N-Heterocyclic Carbene (NHC) Complexes with Cytotoxic Effects in Leukemia Cells.

Sandtorv AH, Leitch C, Bedringaas SL, Gjertsen BT, Bjørsvik HR.

ChemMedChem. 2015 Sep;10(9):1522-7. doi: 10.1002/cmdc.201500234. Epub 2015 Aug 6.

45.

Expression of the potential therapeutic target CXXC5 in primary acute myeloid leukemia cells - high expression is associated with adverse prognosis as well as altered intracellular signaling and transcriptional regulation.

Bruserud Ø, Reikvam H, Fredly H, Skavland J, Hagen KM, van Hoang TT, Brenner AK, Kadi A, Astori A, Gjertsen BT, Pendino F.

Oncotarget. 2015 Feb 20;6(5):2794-811.

46.

Up-regulation of anti-apoptotic genes confers resistance to the novel anti-leukaemic compound PEP005 in primary AML cells.

Hampson P, Wang K, Ersvær E, McCormack E, Schüler J, Fiebig HH, Gjertsen BT, Bruserud Ø, Lord JM.

Oncoscience. 2014 Aug 6;1(8):529-39. eCollection 2014.

47.

Interactions of the natural product (+)-avrainvillamide with nucleophosmin and exportin-1 Mediate the cellular localization of nucleophosmin and its AML-associated mutants.

Mukherjee H, Chan KP, Andresen V, Hanley ML, Gjertsen BT, Myers AG.

ACS Chem Biol. 2015 Mar 20;10(3):855-63. doi: 10.1021/cb500872g. Epub 2015 Jan 5.

48.

Activated regulatory and memory T-cells accumulate in malignant ascites from ovarian carcinoma patients.

Landskron J, Helland Ø, Torgersen KM, Aandahl EM, Gjertsen BT, Bjørge L, Taskén K.

Cancer Immunol Immunother. 2015 Mar;64(3):337-47. doi: 10.1007/s00262-014-1636-6. Epub 2014 Nov 22.

PMID:
25416072
49.

SIRT1 activation by a c-MYC oncogenic network promotes the maintenance and drug resistance of human FLT3-ITD acute myeloid leukemia stem cells.

Li L, Osdal T, Ho Y, Chun S, McDonald T, Agarwal P, Lin A, Chu S, Qi J, Li L, Hsieh YT, Dos Santos C, Yuan H, Ha TQ, Popa M, Hovland R, Bruserud Ø, Gjertsen BT, Kuo YH, Chen W, Lain S, McCormack E, Bhatia R.

Cell Stem Cell. 2014 Oct 2;15(4):431-446. doi: 10.1016/j.stem.2014.08.001.

50.

Dasatinib induces fast and deep responses in newly diagnosed chronic myeloid leukaemia patients in chronic phase: clinical results from a randomised phase-2 study (NordCML006).

Hjorth-Hansen H, Stenke L, Söderlund S, Dreimane A, Ehrencrona H, Gedde-Dahl T, Gjertsen BT, Höglund M, Koskenvesa P, Lotfi K, Majeed W, Markevärn B, Ohm L, Olsson-Strömberg U, Remes K, Suominen M, Simonsson B, Porkka K, Mustjoki S, Richter J; Nordic CML Study Group.

Eur J Haematol. 2015 Mar;94(3):243-50. doi: 10.1111/ejh.12423. Epub 2014 Sep 13.

Supplemental Content

Loading ...
Support Center